Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract

Gulmann, Christian; Paner, Gladell P.; Parakh, Rugvedita; Hansel, Donna E.; Shen, Steven S.; Ro, Jae Y.; Annaiah, Chandrakanth; López-Beltrán, Antonio; Rao, Priya; Arora, Komal; Cho, Yong; Herrera-Hernandez, Loren; Alsabeh, Randa; Amin, Mahul B.

doi:10.1016/j.humpath.2012.05.018

Cited by 80 publications

(54 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since then, several other studies have been published indicating that GATA3 is a highly sensitive and specific urothelialassociated marker that can be used to assist in distinguishing urothelial carcinomas from those neoplasms with which they may be confused. 42,[44][45][46][47] The percentage of GATA3 positivity reported in these investigations is higher than that reported by Higgins et al, 43 ranging from 81% to 100% of the urothelial carcinomas included in these studies. 42,[44][45][46][47] In a combined review of 618 urothelial carcinomas from 6 published studies, 518 (76%) were reported to be GATA3 positive.…”

mentioning

confidence: 78%

“…42,[44][45][46][47] The percentage of GATA3 positivity reported in these investigations is higher than that reported by Higgins et al, 43 ranging from 81% to 100% of the urothelial carcinomas included in these studies. 42,[44][45][46][47] In a combined review of 618 urothelial carcinomas from 6 published studies, 518 (76%) were reported to be GATA3 positive. [42][43][44][45][46][47] When compared with other urothelial-associated markers that have been suggested as being useful in the diagnosis of urothelial carcinomas, GATA3 is more sensitive than uroplakin III, but less sensitive than S100P, thrombomodulin, or p63 (Table 1).…”

mentioning

confidence: 78%

See 1 more Smart Citation

Value of GATA3 Immunostaining in Tumor Diagnosis

Ordóñez

2013

Advances in Anatomic Pathology

117

View full text Add to dashboard Cite

GATA3 is a member of a group of zinc-finger transcription factors that is involved in cell development and differentiation. Recent studies have shown that, among tumors, GATA3 is commonly expressed in both urothelial tumors and breast epithelial neoplasms. With the exception of salivary gland and parathyroid tumors, GATA3 has been reported to be either absent or only rarely expressed in other epithelial tumors. Owing to its restricted expression in urothelial and breast carcinomas, GATA3 has proved to be a useful immunohistochemical marker for assisting in distinguishing these 2 groups of neoplasms from other malignancies with which they may be confused.

show abstract

mentioning

confidence: 78%

mentioning

confidence: 78%

Value of GATA3 Immunostaining in Tumor Diagnosis

Ordóñez

2013

Advances in Anatomic Pathology

117

View full text Add to dashboard Cite

show abstract

“…[150][151][152][153][154][155] Uroplakin does exhibit an extremely high rate of specificity for identifying TCC and is generally not identified in nonurothelial neoplasms. Nevertheless, uroplakin's low rate of sensitivity in invasive and metastatic TCC limits the use of this antibody in the setting of metastatic CUPs and has recently been supplanted by GATA3, the more-sensitive marker of TCC.…”

mentioning

confidence: 99%

Practical Applications in Immunohistochemistry: Carcinomas of Unknown Primary Site

Kandalaft

Gown

2015

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.-Identification of the site of origin of carcinoma of unknown primary using immunohistochemistry is a frequent requirement of anatomic pathologists. Diagnostic accuracy is crucial, particularly in the current era of targeted therapies and smaller sample sizes.Objectives.-To provide practical guidance and suggestions for classifying carcinoma of unknown primary using both proven and new antibodies, as well as targeting panels based on integration of morphologic and clinical features.Data Sources.-Literature review, the authors' practice experience, and authors' research.Conclusions.-With well-performed and interpreted immunohistochemistry panels, anatomic pathologists can successfully identify the site of origin of carcinoma of unknown primary. It is crucial to understand not only the diagnostic uses of the many available antibodies but also the potential limits and pitfalls.

show abstract

“…Pure SCCs are typically positive on immunostains for CK14 and desmoglein-3 and typically negative for GATA-3, uroplakin-III, and S100-P. 9 These latter three are typical of “urothelial” staining pattern and in urothelial carcinoma with squamous differentiation, their expression is reduced compared to pure urothelial carcinomas. 9,10 Also described in the literature is a potential biomarker for urine screening of patients with SCC. In limited studies, the calcium binding protein, psoriasin, typically produced by stratified squamous epithelia, was identified in the urine of four patients with bladder SCC and later identified in six additional patients harboring bladder SCC.…”

Section: Discussionmentioning

confidence: 99%

Unsuspected Malignancy During Percutaneous Nephrolithotomy: The Snake in the Grass

Matulay

Gupta

et al. 2016

Journal of Endourology Case Reports

View full text Add to dashboard Cite

Squamous cell carcinoma of the upper tract (SCC-UT) is a rare neoplasm that disproportionately affects patients with longstanding nephrolithiasis. Diagnosis is challenging and typically comes at late stages; as such, the prognosis is poor. The absence of a reliable diagnostic predictor for SCC highlights the need to keep the diagnosis in mind for at-risk patient populations. In this study, we describe a small case series of rapidly progressive SCC-UT incidentally discovered during percutaneous nephrolithotomy.

show abstract

Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract

Cited by 80 publications

References 30 publications

Value of GATA3 Immunostaining in Tumor Diagnosis

Value of GATA3 Immunostaining in Tumor Diagnosis

Practical Applications in Immunohistochemistry: Carcinomas of Unknown Primary Site

Unsuspected Malignancy During Percutaneous Nephrolithotomy: The Snake in the Grass

Contact Info

Product

Resources

About